Symposia 4 - Quest for Perfection: Updating ‘The Bethesda System for Reporting Thyroid Cytopathology’ (TBSRTC)

The editors (as moderators) and several key lead chapter authors will present the updates and proposed changes to the 3rd (2023) edition of the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). The pivotal role of FNA in the management of patients with thyroid nodules will be highlighted. The symposium will elaborate on diagnostic issues of practical importance. Clinical implications of the various cytopathologic interpretations and TBSRTC categories will be discussed as well as the management guidelines for each diagnostic category in light of the most recent ATA guidelines. The crucial role of a multidisciplinary approach will be emphasized throughout the presentation and there will be a separate discussion on integrating thyroid imaging findings with the FNA diagnoses. The symposium will also include updates on the use of new molecular markers employed to enhance the pre-operative diagnostic accuracy of thyroid FNA as well as used for prognostics and therapeutics (for personalized treatment). The session is being co-sponsored by the ASC and European Federation of Cytology Societies (EFCS).

Target Audience

This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.

Learning Objectives

  • Apply the proposed revised (2023) Bethesda System for Reporting Thyroid Cytopathology in clinical practice
  • Appreciate the new ancillary/molecular tests for the diagnosis, prognosis and personalized treatment
  • Assess the updated clinical implications of cytopathologic interpretations
  • Evaluate the importance of a multidisciplinary approach in thyroid cytopathology
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 California Credits
  • 2.00 CMLE
  • 2.00 Florida Credits
  • 2.00 Participant
Course opens: 
Course expires: 

Syed Ali, MD, FRCPath, CIAC
Manon Auger, MD, FRCP(C)
Zubair Baloch, MD, PhD
Beatrix Cochand Priollett, MD
Barbara Crothers, DO
Tarik Elsheikh, MD
Jeffrey Krane, MD, PhD
Michiya Nishino, MD, PhD
Fernando Schmitt, MD, PhD, FIAC
Christopher VandenBussche, MD, PhD
Paul VanderLaan, MD, PhD

The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.

The following individuals have reported financial relationships:
Michael Berry, SCT(ASCP)MBCM: Stockholder-Hologic
Jeffrey Krane, MD, PhD: Consultant - Hamamatsu Photonics
Oscar Lin, MD, PhD: Consultant – Hologic and Jansen
Liron Pantanowitz, MD: Consultant – Hamamatsu, Advisory Board for Ibex
Martha B. Pitman, MD, FIAC: Consultant – Adenocyte, LLC
Donna K. Russell, MEd, CT(ASCP), HT(ASCP): Advisory Board – Hologic Scientific
Christopher J. VandenBussche, MD, PhD: Ad hoc advisory board panel and Consultant – Roche
Paul VanderLaan, MD, PhD: Consultant – Gala Therapeutics

The following individuals have reported no relevant financial relationships:
Susan A. Alperstein, MS, CT(ASCP), Kristen A. Atkins, MD, Zubair, Baloch, MD, PhD, Guliz A. Barkan, MD, Christine N. Booth, MD, Leigh Ann Cahill, BS, CT(ASCP)CMIAC, Barbara A. Centeno, MD, Deborah J. Chute, MD, Amy C. Clayton, MD, Jacqueline M. Cuda, BS, SCT(ASCP), Fang Fan, MD, PhD, Kara L. Hansing, MEd, SCT(ASCP)CM, Aparna M Mahajan MD, Sara E. Monaco, MD, Michiya Nishino MD, PhD, N. Paul Ohori MD, Lynnette S. Pineault, MBA, SCT(ASCP), Sinchita Roy-Chowdhuri, MD, PhD, Momin T. Siddiqui, MD, FIAC, Z. Laura Tabatabai, MD, Sana O. Tabbara, MD, Michael J. Thrall, MD, Dena M. Tonkovich, BS, CT(ASCP), Dawn L. Underwood, MS, CT(ASCP), Vivian L. Weiss, MD, PhD, Teresa Wood, MPH, BA, CT(ASCP), Lisa Zhang, MD, Syed Ali, MD, FRCPath, CIAC, Manon Auger, MD, FRCP(C), Beatrix Cochand Priollett, MD, Barbara Crothers, DO, Tarik Elsheikh, MD, Fernando Schmitt, MD, PhD, FIAC

The ASC staff associated with the development of content for this activity reported no relevant financial relationships.


Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

American Board of Pathology Maintenance of Certification (CC)
This product can help fulfill the CME requirements mandated by the American Board of Pathology Continuing Certification (CC) process.  Earn up to 2.0 Credit Hours.

Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians.  The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the States of Florida and California. The credit on each link is good for three years from the live presentation date.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 California Credits
  • 2.00 CMLE
  • 2.00 Florida Credits
  • 2.00 Participant


Please login or register to take this course.